News

Legend Biotech Announces Upcoming Q2 2025 Investor Call

Legend Biotech Announces Upcoming Q2 2025 Investor Call

Legend Biotech Unveils Plans for Q2 2025 Investor Call

Legend Biotech Corporation (NASDAQ: LEGN), a pioneering force in cell therapy, is gearing up to host an insightful conference call that is set to take place at 8:00 am ET on an upcoming Monday. This call will provide investors a comprehensive review of the company’s performance in the second quarter of 2025.

What to Expect During the Call

During this important conference call, key leaders from Legend Biotech will share a detailed overview of the company's quarterly performance. They'll dive into the financial results and significant developments, offering valuable insights on how these outcomes align with the company’s strategic goals.

Legends Biotech's Commitment to Innovation

With a workforce of over 2,600 dedicated professionals, Legend Biotech stands as the largest independent cell therapy organization in the industry. It has established a significant footprint in the CAR-T cell therapy sector with its flagship product, CARVYKTI. This innovative treatment, specifically designed for patients with relapsed or refractory multiple myeloma, exemplifies the company's commitment to advancing cancer care through groundbreaking therapies.

Strategic Partnerships Enhancing Development

Partnering with industry giant Johnson & Johnson, Legend Biotech is focused on maximizing patient access to CARVYKTI. This collaboration underscores the company’s ambition to develop transformative therapies that will change the landscape of oncology. By enhancing accessibility to these therapies, Legend Biotech aims to improve patient outcomes significantly.

Future Directions and Expansions

In addition to maintaining its leadership in CAR-T therapy, Legend Biotech is actively expanding its research pipeline with the goal of pioneering new modalities in cell therapy. The company is committed to leveraging its expertise to explore other innovative treatments that could revolutionize patient care in cancer treatment.

About the Company

At its core, Legend Biotech is all about transforming lives through cell therapy. The company’s vision consistently focuses on innovation, patient-centric approaches, and partnerships that can enhance therapeutic access and effectiveness.

How to Participate

For those wishing to participate, Legend Biotech will provide a live audio webcast of the conference call. Given the significant developments anticipated in this quarterly report, investors are encouraged to join the call to stay updated on the company’s progress and future plans.

Accessing Past Recordings

Following the call, a replay of the conference and relevant earnings news release will be available. Investors can find this information in the Investor Relations section of the official website, ensuring they're always informed about the latest developments at Legend Biotech.

Contact Information

If you have further inquiries, feel free to reach out to Legend Biotech’s investor relations team. Jessie Yeung, who handles investor relations, is available for any questions you may have regarding the conference call.

Investor and Media Contacts

For investment-related inquiries, please contact Jessie Yeung at (732) 956-8271 or via email at jessie.yeung@legendbiotech.com. Additionally, for media questions, Mary Ann Ondish can be reached at (914) 552-4625 or by emailing media@legendbiotech.com.

Frequently Asked Questions

When is the investor call scheduled?

The investor call will be held on a Monday at 8:00 am ET.

What will be discussed during the call?

Key leaders will discuss Legend Biotech’s second quarter 2025 results and overall performance.

How can I access the conference call?

You can join the live audio webcast provided by Legend Biotech's Investor Relations section on their official website.

Where can I find the replay of the call?

The replay and earnings news release will be posted in the Investor Relations section of Legend Biotech’s website about two hours after the call concludes.

Who should I contact for more information?

For inquiries about the investor call, reach out to Jessie Yeung at jessie.yeung@legendbiotech.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Teamsters Secure Landmark Deal for SF Parking Workers

Updated Category News Views 5

Major Win for San Francisco's Parking Professionals Parking lots and garages across San Francisco might not be the first places you’d look for labor triumphs, but that’s exactly what almost 1,000 members of Teamsters Local 665 have achieved. Under a newly ratified four-year master contract, these parking pros snagged one of the richest deals the industry has seen. A...

Continue Reading
Bill Evans Enhances Gateway's Wealth Management Expertise

Updated Category News Views 2

Welcome Aboard, Bill Evans Some days the financial world throws a gem your way, something worth more than a rat-race racehorse in a shattered stock rally. Meet Bill Evans, a seasoned professional stepping into the vibrant arena of Gateway Financial Partners. He’s put in 29 years around the investment block, and now he’s parking himself in Glastonbury, Connecticut, set...

Continue Reading
CME Group Unveils First Baseball Futures Market

Updated Category News Views 6

A New Pitch in the Financial Ballpark Alright, listen up: CME Group is stepping up to the plate with a game-changer. They’re rolling out the world’s first baseball futures, launching October 12, assuming regulators give the green light. Now, this isn’t just some novelty act; it’s based on the solid groundwork of their FutureSports Performance Indexes (CME FSPI),...

Continue Reading
Ingram Mercantile's Aviation Push: SCORE or Sink?

Updated Category News Views 1

Unpacking Neobanx's Strategic Play Straight off the tarmac, Neobanx launches Ingram Mercantile, placing their bets on the aviation sector with none other than Eli Stepp at the helm. This ain't just another day in the sky for those in the know; it's part of a gutsy bid to inject some high-octane intelligence into the world of retail. I mean, have you seen the landscape...

Continue Reading
Steel Dynamics Gears Up for Q3 2026 Earnings Update

Updated Category News Views 7

Steel Dynamics Preps for Key Earnings Report Folks, we're staring down the barrel of another quarterly earnings report from Steel Dynamics, Inc., and you can bet this one is gonna have plenty of eyes glued. October 19th, 2026, that's when they'll peel back the curtain on how they fared in Q3. Now, buckle up, because this isn't just a numbers game—it’s a snapshot of...

Continue Reading
Lupin Secures FDA Nod for Key Injectable Drug

Updated Category News Views 4

Lupin's FDA Approval: A Strategic Play in Pharmaceuticals Ah, the thrill of a new approval! Lupin Limited has landed U.S. FDA approval for their Phytonadione Injectable Emulsion, marking a significant stride into the lucrative realm of vitamin K treatments. This approval isn't just a feather in Lupin's cap—it's a calculated move to corner a piece of the estimated $52.3...

Continue Reading
Mexico's Beaches Shine in 2026 Best America Rankings

Updated Category News Views 5

Mexican Shores Turning Heads in 2026 This isn’t just another wave in tourism news; it’s a tidal shift towards Mexico’s sizzling beaches claiming some prime spots on the global travel stage. If you’ve got an eye for tourism dynamics, listen up because Mexico’s sun-soaked shores just snagged six spots among the top 20 beaches in the Americas, according to the...

Continue Reading
Protecting Your Family on Halloween: Safety Tips

Updated Category News Views 5

Avoid Turning Halloween Fun Into a Medical Emergency Halloween should be about ghosts and ghouls, not a dreaded detour to the ER. Yet, every year, adults and kids get carried away with costumes, only to find themselves in a real-life horror show courtesy of a slip, a fall, or a carving mishap. The American Academy of Orthopaedic Surgeons (AAOS) is waving the safety flag,...

Continue Reading
Icebox Takes on Buckhead with Diamonds and Discounts

Updated Category News Views 2

So, Atlanta's Icebox Diamonds & Watches just dropped a news bomb that could shake up anyone with a taste for glitz and a wallet ready to act. This iconic jeweler, swinging its roots from a humble family biz to a global gem, is opening up its vault with an Inventory Reduction Sale starting October 9. And folks, it’s happening right at their Buckhead flagship showroom....

Continue Reading
Raken Debuts Change Orders: A Game-Changer for Builds

Updated Category News Views 4

Construction Gets a Streamlined Boost with Raken's New Tool In construction, chaos often partners seamlessly with progress. But Raken is stepping in to shake things up a bit. This isn’t just another run-of-the-mill software update; this is Raken flexing its muscles in the construction tech arena. They’ve rolled out Change Orders, enhancing their project management...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Surge of Multi-Access Edge Computing Market Growth

Updated Category News Views 119

Understanding the Multi-Access Edge Computing Market As we delve into the increasingly impactful world of Multi-Access Edge Computing (MEC), it's essential to recognize the significant growth trajectory this sector is experiencing. The MEC market, currently valued at USD 3.40 billion, is projected to reach a staggering USD 121.86 billion by 2032, showing a remarkable...

Continue Reading
Exciting Community Events at Sherwood Ford This October

Updated Category News Views 247

Sherwood Ford's Commitment to the Community Sherwood Ford is a dealership that truly embraces its role within the community by hosting various events aimed at bringing people together. This October, two major initiatives are coming to life: the Fill a Ford Food Drive and the much-anticipated Ford Dealer Days. These events are a chance not just to have fun, but also to...

Continue Reading
China's Economy Shows Positive Momentum for 2025 Growth

Updated Category News Views 302

China's Economic Resilience and Future Outlook Recently, China's economy has demonstrated remarkable resilience, bouncing back from earlier challenges with solid momentum. This uptrend can be attributed to a variety of macroeconomic policies enacted to stimulate growth. Indicators show that industry and service sectors are on a growth trajectory, bolstered by rising...

Continue Reading
DTE Energy's Earnings: What Traders Need to Watch Preview

Updated Category News Views 145

DTE Energy (NYSE:DTE) is set to unveil its quarterly earnings on February 17, 2026. The buzz around this event isn’t just about the numbers; it’s a high-stakes game where investor sentiment can shift dramatically based on earnings and subsequent guidance. Analysts are bracing for an earnings per share (EPS) of $1.52. But don’t get lost in the headline figure—what...

Continue Reading
BofA Adjusts Zegna Stock Outlook Amid Global Luxury Challenges

Updated Category News Views 96

BofA Revises Zegna Stock Outlook Amid Global Luxury Challenges Recently, BofA Securities caught attention by changing its outlook on Ermenegildo Zegna Group (NYSE: ZGN), downgrading its recommendation from Buy to Neutral. This notable shift includes a reduced price target of $9.80, a drop from the previous $13.00. This decision stems from concerns regarding Zegna’s...

Continue Reading